8-K: Performant Financial Corporation Appoints Dr. Shantanu Agrawal to Board of Directors

Performant Financial Corporation has appointed Dr. Shantanu Agrawal to its Board of Directors, expanding the board to seven members.

Summary

• Performant Financial Corporation has appointed Dr. Shantanu Agrawal to its Board of Directors, effective March 1, 2024.
• Dr. Agrawal's appointment increases the board size from six to seven directors.
• He will serve as a Class I director with a term expiring at the company's 2025 Annual Meeting of Stockholders.
• Dr. Agrawal will receive an annual retainer of $40,000, prorated for this year, and an initial restricted stock unit (RSU) award valued at $100,000.
• The RSU award will vest in four equal annual installments over four years, or upon a Change of Control.
• He will also be eligible for annual RSU awards and will enter into an indemnification agreement with the company.

Sentiment

Score: 7

Explanation: The document reflects a positive development with the appointment of a qualified board member, but it is a routine corporate event and not a major catalyst for significant positive sentiment.

Positives

• The appointment of Dr. Agrawal brings significant healthcare expertise to the board, given his background as Chief Health Officer at Elevance Health and his previous roles at the National Quality Forum and CMS.
• His experience in healthcare quality, program integrity, and policy is expected to provide valuable insights to the board.
• The expansion of the board to seven members may bring a broader range of perspectives and expertise to the company's governance.

Future Outlook

Dr. Agrawal will be eligible for annual RSU awards under the company's Stock Incentive Plan, consistent with the board's compensation policies.

Management Comments

• Dr. Agrawal's clinical and business expertise provides valuable insight for the members of the Board.

Industry Context

The appointment of a healthcare expert like Dr. Agrawal to the board suggests a strategic focus on healthcare-related business opportunities and compliance, which is relevant given Performant's operations in the healthcare sector.

Comparison to Industry Standards

• The compensation package for Dr. Agrawal, including an annual retainer and RSU awards, is consistent with standard practices for board members in publicly traded companies.
• The vesting schedule of the RSU award over four years is a common practice to ensure long-term alignment with the company's interests.
• Indemnification agreements are standard for board members to protect them from potential liabilities related to their service.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of Dr. Agrawal positively, given his expertise and potential contribution to the company's strategic direction.
• The appointment does not have a direct impact on employees, customers, suppliers, or creditors.

Next Steps

• Dr. Agrawal will serve as a Class I director until the 2025 Annual Meeting of Stockholders.
• The Board may consider appointing Dr. Agrawal to one or more committees of the Board in the future.

Key Dates

Keywords

Board of Directors, Director Appointment, Corporate Governance, Healthcare, Executive Compensation, Restricted Stock Units, Indemnification, Performant Financial Corporation